Silvant Capital Management’s Bristol-Myers Squibb BMY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $357K | Hold |
5,887
| – | – | 0.01% | 179 |
|
|
2025
Q4 | $318K | Sell |
5,887
-32,702
| -85% | -$1.57M | 0.01% | 176 |
|
|
2025
Q3 | $1.74M | Buy |
38,589
+4,198
| +12% | +$196K | 0.06% | 138 |
|
|
2025
Q2 | $1.59M | Sell |
34,391
-248
| -0.7% | -$12.2K | 0.06% | 137 |
|
|
2025
Q1 | $2.11M | Buy |
34,639
+616
| +2% | +$35.9K | 0.1% | 121 |
|
|
2024
Q4 | $1.92M | Sell |
34,023
-213
| -0.6% | -$11.9K | 0.08% | 125 |
|
|
2024
Q3 | $1.77M | Sell |
34,236
-804
| -2% | -$37.7K | 0.08% | 127 |
|
|
2024
Q2 | $1.46M | Sell |
35,040
-420
| -1% | -$18.8K | 0.06% | 132 |
|
|
2024
Q1 | $1.92M | Buy |
35,460
+1,847
| +5% | +$94.1K | 0.09% | 124 |
|
|
2023
Q4 | $1.72M | Sell |
33,613
-4,357
| -11% | -$229K | 0.09% | 119 |
|
|
2023
Q3 | $2.2M | Sell |
37,970
-1,555
| -4% | -$95.3K | 0.13% | 101 |
|
|
2023
Q2 | $2.53M | Buy |
39,525
+2,215
| +6% | +$149K | 0.14% | 99 |
|
|
2023
Q1 | $2.59M | Sell |
37,310
-638
| -2% | -$45K | 0.17% | 96 |
|
|
2022
Q4 | $2.73M | Buy |
37,948
+543
| +1% | +$40.9K | 0.19% | 94 |
|
|
2022
Q3 | $2.66M | Sell |
37,405
-184
| -0.5% | -$13.3K | 0.18% | 92 |
|
|
2022
Q2 | $2.92M | Buy |
37,589
+58
| +0.2% | +$4.42K | 0.71% | 32 |
|
|
2022
Q1 | $2.76M | Sell |
37,531
-414
| -1% | -$27.8K | 0.53% | 48 |
|
|
2021
Q4 | $2.37M | Sell |
37,945
-1,491
| -4% | -$87.5K | 0.4% | 60 |
|
|
2021
Q3 | $2.35M | Sell |
39,436
-6,826
| -15% | -$450K | 0.42% | 62 |
|
|
2021
Q2 | $3.09M | Sell |
46,262
-725
| -2% | -$47.3K | 0.49% | 50 |
|
|
2021
Q1 | $2.99M | Sell |
46,987
-1,264
| -3% | -$78.6K | 0.51% | 50 |
|
|
2020
Q4 | $3.02M | Sell |
48,251
-847
| -2% | -$52.1K | 0.52% | 48 |
|
|
2020
Q3 | $2.96M | Sell |
49,098
-11,615
| -19% | -$699K | 0.55% | 44 |
|
|
2020
Q2 | $3.57M | Sell |
60,713
-3,681
| -6% | -$220K | 0.64% | 37 |
|
|
2020
Q1 | $3.59M | Sell |
64,394
-1,166
| -2% | -$71.3K | 0.78% | 29 |
|
|
2019
Q4 | $4.21M | Sell |
65,560
-50
| -0.1% | -$2.86K | 0.77% | 31 |
|
|
2019
Q3 | $3.33M | Sell |
65,610
-9,310
| -12% | -$438K | 0.66% | 44 |
|
|
2019
Q2 | $3.4M | Sell |
74,920
-6,551
| -8% | -$305K | 0.61% | 51 |
|
|
2019
Q1 | $3.89M | Sell |
81,471
-3,165
| -4% | -$158K | 0.7% | 40 |
|
|
2018
Q4 | $4.4M | Sell |
84,636
-2,336
| -3% | -$126K | 0.88% | 27 |
|
|
2018
Q3 | $5.4M | Sell |
86,972
-13,363
| -13% | -$793K | 0.67% | 50 |
|
|
2018
Q2 | $5.55M | Sell |
100,335
-1,108
| -1% | -$59.8K | 0.69% | 47 |
|
|
2018
Q1 | $6.42M | Buy |
+101,443
| New | +$6.53M | 0.82% | 36 |
|
Other funds holding BMY
VCM
VPM
Silvant Capital Management's BMY Position: Q1 2026 in Review
Silvant Capital Management held its Bristol-Myers Squibb (BMY) position steady in Q1 2026 at 5,887 shares worth $357K. The position accounts for 0.01% of the portfolio, ranked #179.
Silvant Capital Management first reported a position in BMY in Q1 2018 and has held it in 33 quarters since. The position peaked at $6.42M in Q1 2018. 2,520 funds tracked by Wall St. Rank hold BMY as of Q1 2026.
- Silvant Capital Management held 5,887 shares of Bristol-Myers Squibb worth $357K as of Q1 2026.
- Silvant Capital Management left its Bristol-Myers Squibb share count unchanged in Q1 2026.
- Bristol-Myers Squibb made up 0.01% of Silvant Capital Management's portfolio in Q1 2026, its #179 holding.
- Silvant Capital Management first reported a position in Bristol-Myers Squibb in Q1 2018 and has held it in 33 quarters since.
- Silvant Capital Management's Bristol-Myers Squibb position peaked at $6.42M in Q1 2018.
- 2,520 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2026.
Based on Silvant Capital Management's 13F filing for Q1 2026, filed 14 May 2026.